Details of the Drug

General Information of Drug (ID: DMT17XU)

Drug Name
131I-radretumab
Synonyms
L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0H4GT

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin beta-1 (ITGB1) TTBVIQC ITB1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01242943) Radioimmunotherapy With 131I-L19SIP in Patients With Cancer. U.S. National Institutes of Health.
2 Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.